Sfoglia per Autore
Mostrati risultati da 1 a 9 di 9
Proposal of a non-invasive approach for biomechanical follow-up of heart failure patients.
2008 I. Corazza; E. Tartagni; F. Marangoni; R. Zannoli
Nutraceuticals with lipid-lowering activity: do they have any effect beyond cholesterol reduction?
2012 Cicero AFG; Tartagni E; Borghi C.
Antidiabetic properties of berberine: from cellular pharmacology to clinical effects.
2012 Cicero A.F.G.; Tartagni E
Dietary determinants of oxidized-low-density lipoprotein antibodies in a sample of pharmacologically untreated non-smoker subjects: data from the Brisighella heart study.
2013 Cicero AF; Reggi A; Tartagni E; Grandi E; D'Addato S; Borghi C; Brisighella Heart Study
Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence.
2014 Cicero AF; Tartagni E; Ertek S.
Nutraceuticals for metabolic syndrome management: from laboratory to benchside.
2014 Cicero AF; Tartagni E; Ertek S.
Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data
2014 Cicero AF; Tartagni E; Ertek S.
Diet, dietary supplements and age-related macular degeneration (AMD)
2014 Cicero AFG.; Tartagni E.
2B02: SERUM URIC ACID LEVEL, BUT NOT RENAL FUNCTION OR ARTERIAL STIFFNESS, IS ASSOCIATED TO WORSE BLOOD PRESSURE CONTROL IN GENERAL PRACTICE: DATA FROM THE BRISIGHELLA HEART STUDY
2015 Cicero, A; Rosticci, M; Tartagni, E; Parini, A; Grandi, E; D'Addato, S; Borghi, C; Group, Bhs
Mostrati risultati da 1 a 9 di 9
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile